GNI has in-licensed a late-stage hepatitis drug from EpiCept. GNI now owns the rights for EP1013 in Asia, Australia and New Zealand, while EpiCept retains control of the drug in the rest of the world. GNI, which is based in Japan, will put its wholly-owned China subsidiary, Shanghai Genomics, in charge of the pre-IND and clinical development of EP1013. GNI has another hepatitis drug already in development, F351, for liver fibrosis. More details...

Stock Symbols: (TOKYO: 2160) (NSDQ: EPCT)